STOCK TITAN

Adial Pharmaceuticals Inc - ADIL STOCK NEWS

Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.

Adial Pharmaceuticals Inc (ADIL) is a clinical-stage biopharmaceutical company pioneering personalized treatments for alcohol use disorder through advanced pharmacogenomics. This page provides investors and healthcare professionals with essential updates on ADIL's clinical trials, regulatory milestones, and strategic initiatives.

Access timely announcements about the company's lead investigational drug AD04—a serotonin-3 receptor antagonist designed for genetically identified patient groups. Stay informed about clinical study results, FDA communications, intellectual property developments, and partnership opportunities that demonstrate ADIL's progress in addiction medicine.

Key updates include progress reports on the 505(b)(2) regulatory pathway, companion diagnostic advancements, and peer-reviewed research publications. All content is curated to help stakeholders track the company's evidence-based approach to treating addictive disorders through precision medicine.

Bookmark this page for direct access to primary source materials and analysis-free reporting on ADIL's scientific and corporate developments. Check regularly for new filings, trial data disclosures, and strategic announcements that shape the company's trajectory in biopharmaceutical innovation.

Rhea-AI Summary

Adial Pharmaceuticals has started dosing the first patient in a pharmacokinetics study of AD04, targeting Alcohol Use Disorder (AUD). This significant milestone is part of the preparation for the U.S. Pivotal Phase 3 trials and aims to optimize study design elements.

The study, expected to last 6 months, will help determine the optimal dosing regimen and fulfill FDA requirements for Phase 3. Results are anticipated in early Q4 2024.

This study is a important component in Adial’s strategy to advance partnership discussions and support a 505(b)(2) regulatory pathway application. The study involves two cohorts and up to 30 healthy adult volunteers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
none
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company specializing in addiction therapies, will participate in the Spring MicroCap Rodeo Conference on June 6, 2024, in New York City.

CEO Cary Claiborne will present at 2:00 p.m. ET, with the presentation available via live webcast.

Adial's management will also conduct one-on-one meetings with approved investors throughout the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences
-
Rhea-AI Summary

Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company, reported its Q1 2024 financial results and provided a business update. The company is advancing its lead drug, AD04, with plans for two parallel Phase 3 trials, following positive FDA feedback. Key patents were awarded for AD04's effectiveness in treating addiction disorders, marking a potential $40 billion market in the U.S.

Financially, Adial's cash and equivalents rose to $5 million, bolstered by $4.3 million from recent warrant exercises. However, net loss increased to $6.5 million, primarily due to a $4.5 million non-cash warrant issuance charge. R&D expenses rose by $88K, while G&A expenses decreased by $512K.

Additionally, a peer-reviewed article highlighted AD04's promising clinical results and safety profile. New COO Tony Goodman is expected to drive forward strategic growth and clinical initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
Rhea-AI Summary
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, has been granted a key patent by the United States Patent and Trademark Office. The patent covers the combination of the Company's genetic diagnostic with their lead investigational drug, AD04, for the treatment of alcohol use disorder and other drug dependencies. This patent expands Adial's intellectual property protection and opens up a significant market opportunity in the U.S. healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals announces positive results from a peer-reviewed article highlighting the safety and efficacy of AD04 in treating Alcohol Use Disorder (AUD) without significant adverse effects. The study emphasizes the liver safety profile of AD04 compared to placebo, indicating promising clinical outcomes and high patient compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
106.19%
Tags
-
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) provided a business update and reported financial results for the 2023 fiscal year. The company made significant progress towards the potential approval and commercial launch of its lead investigational new drug product, AD04, to treat Alcohol Use Disorder. Adial received positive feedback from US and EU regulators, engaged expert advisors, and is finalizing its clinical development plan. Discussions with potential strategic partners are advancing, and the company received $4.3 million in gross proceeds from warrant exercises. Adial also announced key patents related to genetic diagnostics for the treatment of Alcohol Use Disorder and opioid use disorder. The company received awards for technology innovation and completed a reimbursement agreement with Adovate, Financially, Adial reported $2.8 million in cash and cash equivalents, with total gross proceeds of $4.3 million from warrant exercises. Research and development expenses decreased by 35%, and general and administrative expenses decreased by 37%. The net loss for 2023 was $5.1 million, an improvement from the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Adial Pharmaceuticals, Inc. announces the immediate exercise of warrants, raising $3.5 million. H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.64%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals strengthens its patent portfolio with a new patent covering AD04's ability to target the serotonin transporter gene for treating opioid use disorder. The patent was issued by the United States Patent and Trademark Office, highlighting the company's commitment to developing therapies for addiction and related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
86.21%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announces participation in Winter Wrap-Up MicroCap Rodeo Conference. CEO Cary Claiborne to present on February 20, 2024, and host one-on-one meetings with investors. Register at webcaster4.com and MicroCap Rodeo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences
Rhea-AI Summary
Adial Pharmaceuticals expands its patent estate to cover a unique genetic diagnostic approach for treating alcohol and drug dependencies. The Company's lead drug, AD04, shows promising results in specific genotype patients, potentially revolutionizing addiction treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.85%
Tags
none
Adial Pharmaceuticals Inc

Nasdaq:ADIL

ADIL Rankings

ADIL Stock Data

4.51M
6.48M
1.75%
9.58%
10.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHARLOTTESVILLE